| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
1 Arizona Cancer Center, 2 Department of Molecular and Cellular Biology, and 3 Department of Pathology, University of Arizona, Tucson, Arizona; 4 The Ontario Cancer Institute and the Department of Laboratory Medicine and Pathobiology, Toronto, Ontario, Canada; and 5 GeneTrove, Functional Genomics Division of Isis Pharmaceuticals Inc., Carlsbad, California
Requests for Reprints: Phillip J. Gray Jr., Arizona Cancer Center, Room 3916, 1515 North Campbell Avenue, Tucson, AZ 85724. Phone: (520) 626-8452; Fax: (520) 626-6898. E-mail: pjgray{at}email.arizona.edu
Pancreas cancer is the fourth leading cause of cancer-related death in adults in the United States. New molecular targets for diagnosis and therapy of this disease are desperately needed. In this study, we report on the mitotic serine-threonine kinase polo-like kinase 1 (Plk1) in pancreatic cancer. Plk1 mRNA was found to be overexpressed in 9 of 10 tested pancreatic cancer cell lines and in 4 of 4 tested human tumors. Immunohistochemical staining of a pancreatic tissue microarray showed that 26 of the 35 tumors taken directly from patients overexpressed Plk1. We also examined the effects of depleting Plk1 in pancreatic cancer cells by the use of antisense oligonucleotides. Antisense-treated pancreatic cancer cells showed cell cycle arrest in G2-M as well as a drastic reduction in proliferation rates. These data suggest that Plk1 is a potential therapeutic target in devising a treatment for patients with pancreatic cancer.
Key Words: Polo-like kinase • Molecular drug target • Cell cycle • Pancreatic cancer • Antisense • Oligonucleotides
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Received 6/24/03; revised 2/ 2/04; accepted 2/11/04.
This article has been cited by other articles:
|
|
 |
|
  D. Mahadevan and D. D. Von Hoff Tumor-stroma interactions in pancreatic ductal adenocarcinoma Mol. Cancer Ther., April 1, 2007; 6(4): 1186 - 1197. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. L. Warner, R. M. Munoz, P. Stafford, E. Koller, L. H. Hurley, D. D. Von Hoff, and H. Han Comparing Aurora A and Aurora B as molecular targets for growth inhibition of pancreatic cancer cells. Mol. Cancer Ther., October 1, 2006; 5(10): 2450 - 2458. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. L. Garland, C. Taylor, D. L. Pilkington, J. L. Cohen, and D. D. Von Hoff A Phase I Pharmacokinetic Study of HMN-214, a Novel Oral Stilbene Derivative with Polo-Like Kinase-1-Interacting Properties, in Patients with Advanced Solid Tumors Clin. Cancer Res., September 1, 2006; 12(17): 5182 - 5189. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Astrinidis, W. Senapedis, and E. P. Henske Hamartin, the tuberous sclerosis complex 1 gene product, interacts with polo-like kinase 1 in a phosphorylation-dependent manner Hum. Mol. Genet., January 15, 2006; 15(2): 287 - 297. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
